Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
Healthcare
$0.81 -3.39%
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
52W Low $1.09High $1.95
Volume 0.15M
Average 0.49M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$150.07M
FY 2025 · Annual
Net Income
-$149.34M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| 35.85M | 42.02M | 58.72M | 60.54M | 61.37M | |
| 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
PLRX Earnings Waterfall · TTM
NASDAQ:PLRX · Revenue to Net Income
Key Ratios
EPS$-1.84
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$113.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.84, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 2, 2026 | |
| SC 13G | SC 13G filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| 8-K | Current report | Aug 11, 2026 |
How much revenue does PLRX generate?
Pliant Therapeutics, Inc. (PLRX) reported $0.00 of revenue in fiscal 2025.
Is PLRX profitable?
Pliant Therapeutics, Inc. (PLRX) reported -$149.34M of net income.
Continue the stock analysis
Jump to another research area for this company.